Currency In USD
| Previous Close | 47.73 |
| Open | 49 |
| Day High | 49 |
| Day Low | 45.82 |
| 52-Week High | 72.36 |
| 52-Week Low | 20.18 |
| Volume | 74,337 |
| Average Volume | 482,265 |
| Market Cap | 1.4B |
| PE | -43.22 |
| EPS | -1.08 |
| Moving Average 50 Days | 51.33 |
| Moving Average 200 Days | 50.57 |
| Change | -1.05 |
Anaptys Announces Participation at Upcoming Investor Conferences
GlobeNewswire Inc.
Feb 05, 2026 9:15 PM GMT
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer o
Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary
GlobeNewswire Inc.
Jan 08, 2026 11:00 PM GMT
Trial to resolve all claims in the Anaptys and Tesaro/GSK dispute is scheduled for July 14-17, 2026 SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovativ
Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 06, 2026 9:15 PM GMT
SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer o